Full Text
PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

Abstract

Authors

MG Saggia EA Santos V Nasciben

Back to Volume 11, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×